Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

AbbVie, Teva, Others Score Early Win in Bystolic Antitrust Case

Jan. 24, 2022, 6:37 PM

AbbVie Inc. and a group of generic drug manufacturers notched an initial victory Monday against antitrust litigation over their alleged scheme to delay generic versions of the blood pressure medication Bystolic, when a federal judge in Manhattan tentatively tossed the consolidated case.

Judge Lewis J. Liman dismissed a pair of proposed class actions without prejudice from the U.S. District Court for the Southern District of New York, where a group of pension funds and retail pharmacies are pursuing claims on behalf of end payers and resellers, respectively.

Liman’s ruling came in a sealed opinion that’s due to be made public ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.